
Claims

1. Use of an antibody-drug conjugate in the manufacture of a medicament for treating cancer, wherein the antibody-drug conjugate is to be administered in combination with an anti-SIRPα antibody, wherein the antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula is conjugated to an antibody via a thioether bond:



wherein A represents the connecting position to the antibody.

2. The use according to claim 1, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, or an anti-CDH6 antibody.

3. The use according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

4. The use according to claim 3, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO: 2.

5. The use according to claim 3, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 1 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 2.

6. The use according to any one of claims 3 to 5, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.

7. The use according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

8. The use according to claim 7, wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence represented by SEQ

ID NO: 3 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 4.

9. The use according to claim 7, wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 446 of SEQ ID NO: 3 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 4.

10. The use according to any one of claims 7 to 9, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.

11. The use according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

12. The use according to claim 11, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO: 5 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 6.

13. The use according to claim 11, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain

consisting of an amino acid sequence consisting of amino acid residues 20 to 469 of SEQ ID NO: 5 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 6.

14. The use according to any one of claims 11 to 13, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 3.5 to 4.5.

15. The use according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

16. The use according to claim 15, wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 7 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO: 8.

17. The use according to claim 15, wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO: 7 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO: 8.

18. The use according to any one of claims 15 to 17, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 3.5 to 4.5.

19. The use according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.

20. The use according to claim 19, wherein the anti-GPR20 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO: 9 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 10.

21. The use according to claim 19, wherein the anti-GPR20 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 9 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 10.

22. The use according to any one of claims 19 to 21, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.

23. The use according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

24. The use according to claim 23, wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 11 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO: 12.

25. The use according to claim 23, wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO: 11 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO: 12.

26. The use according to any one of claims 23 to 25, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.

27. The use according to any one of claims 1 to 26, wherein the anti-SIRPα antibody is any one of the following antibodies (1) to (5):

(1) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid

residues 20 to 466 of SEQ ID NO: 13 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 16;

(2) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 13 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 17;

(3) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 14 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 15;

(4) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 14 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 16; and

(5) an antibody according to any one of (1) to (4), lacking a lysine residue at the carboxyl terminus of the heavy chain.

28. The use according to any one of claims 1 to 27, wherein the antibody-drug conjugate and the anti-SIRPα antibody are separately contained as active components in different formulations, and are to be administered simultaneously or at different times.

29. The use according to any one of claims 1 to 28, wherein the cancer is at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, salivary gland cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine cancer, sarcoma, head and neck cancer, hepatocellular cancer, cervical cancer, brain tumor, glioma, eye tumor, thyroid cancer, thymus cancer, gallbladder cancer, lymphoma, leukemia, and myelodysplastic syndrome.

30. A pharmaceutical composition comprising an antibody-drug conjugate and an anti-SIRPα antibody, wherein the antibody-drug conjugate and the anti-SIRPα antibody are as defined in any one of claims 1 to 27.

31. A kit of parts comprising:

(A) an antibody-drug conjugate as defined in any one of claims 2 to 26; and

(B) an anti-SIRPα antibody as defined in claim 27, as a combined preparation for simultaneous, separate or sequential use in cancer therapy.